Who founded Thymmune?

Thymmune was founded by Stan Wang, Bing Lim.

Who are Thymmune's investors?

Thymmune's investors include Pillar VC, NYBC Ventures.

How much funding has Thymmune raised?

Thymmune has disclosed $7M raised across 1 round.

Where is Thymmune headquartered?

Thymmune is headquartered in Cambridge, US.

Thymmune

Cambridge, US · 2 known investors

Find your way into Thymmune

667 people in our graph share verified history with the Thymmune team — schools, employers, funds. One of them is your warm intro.

Veronica Breckenridgeunlockedknows Stan Wang · together at The Council on Strategic Risks (overlapped)

×2knows the team · via Sana Biotechnology

×9knows the team · via A*STAR - Agency for Science, Technology and Research

Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.

AI & Machine Learning Biotech Longevity

Founders & leadership

Stan Wang MD, PhDStan Wang holds an MD from Columbia University (via the NIH Medical Scientist Training Program) and a PhD in stem cell biology and regenerative medicine from the University of Cambridge (as a Gates Scholar and NIH-Cambridge Scholar). He was a postdoctoral fellow with George Church at Harvard Medical School and served as Founding Chief Scientific Officer at Cellino Biotech before founding Thymmune Therapeutics, which develops iPSC-derived thymic cell therapies for immunodeficiencies and related disorders.

Bing Lim MD, PhDBing Lim is an MD/PhD physician-scientist with 27 years of research experience at Harvard Medical School and the Genome Institute of Singapore, where his lab developed methods for pluripotent stem cell differentiation and identified markers and therapeutic targets in tumor-initiating cells. He previously held leadership roles in cell therapy and drug discovery at Sana Biotechnology (Senior Vice President) and Merck (Associate Vice President), where he led efforts in stem cell manipulation and translational development, as well as target identification and validation.

Manish Jain Manish Jain is a senior operations and manufacturing executive with 20+ years in biotech and biopharma, with expertise in CMC development, process engineering, regulatory strategy, and scaling cell and protein therapies from early stage through commercial production.

Investors · 2

Pillar VC✓ confirmed by ThymmuneBoston · $50K – $4M

How we know: Pillar VC's portfolio page · the company's own site · funding news · Not right? Tell us

NYBC Ventureslisted by NYBC VenturesNew York

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

$7M disclosed across 1 round · 2023

$7MSeedMar 2023 · 2 sources
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal — Thymmune Therapeuticsthymmune.com · Mar 2023

Frequently asked questions

What does Thymmune do?: Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.
Who founded Thymmune?: Thymmune was founded by Stan Wang, Bing Lim.
Who are Thymmune's investors?: Thymmune's investors include Pillar VC, NYBC Ventures.
How much funding has Thymmune raised?: Thymmune has disclosed $7M raised across 1 round.
Where is Thymmune headquartered?: Thymmune is headquartered in Cambridge, US.